DCTH — DELCATH SYSTEMS, INC.

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 872912 ·
Last close
$19.37
Market Cap
$673.84M
52W High
$22.51
52W Low
$8.12
ADV30
621,023
Next earnings
2026-11-09
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 35,102,000 31,184,000 7,116,000 6,952,000 149,090,000 55,538,000 15,553,000
Jun 2026 29,133,000 26,148,000 2,395,000 2,668,000 137,018,000 47,521,000 15,873,000
Mar 2026 24,994,000 21,258,000 -1,637,000 -1,070,000 124,838,000 41,313,000 12,128,000
Dec 2025 20,728,000 17,718,000 -2,184,000 -1,896,000 123,632,000 43,454,000 12,413,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$22,993,000
Investing CF
$-2,896,000
Financing CF
$-6,267,000
CapEx
$-2,883,000
Dividends Paid
—
Buybacks
$-3,011,000
EPS Diluted TTM
$0.16
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-520,298,000
Inventory
$10,501,000
Receivables
$20,815,000
ST Investments
$48,777,000
EBIT TTM
$5,690,000
Pretax Income TTM
$8,884,000
Interest Exp TTM
—
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$109,957,000
EBITDA
$6,138,000
Free Cash Flow
$19,479,250
Enterprise Value
$612,987,776
Total Cash
$104,315,000
Total Debt
$2,408,000
Shares Out
34,788,068
Trailing EPS
$0.16
Book Value
$3.84
ROE
5.4%
ROA
2.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 85,231,000 660,000 2,700,000 123,632,000 12,413,000 111,219,000 22,516,000
Dec 2024 37,205,000 -12,410,000 -26,386,000 76,589,000 7,843,000 68,746,000 -18,681,000
Dec 2023 2,065,000 -38,182,000 -47,678,000 38,613,000 22,836,000 15,777,000 -31,251,000
Dec 2022 2,719,000 -33,853,000 -36,508,000 17,862,000 23,721,000 -5,859,000 -24,950,000

TTM Snapshot

Revenues TTM
$95,418,000
NetIncome TTM
$532,000
OpCashFlow TTM
—
Assets (Latest)
$137,018,000
Forward EPS
$0.27

Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $12.50 · spot: $19.70 · call volume: 25 · put volume: 201

Peers — same industry

TickerNameMarket CapLastDaily %
BVS Bioventus Inc. $725.83M $10.60 —
INMD InMode Ltd. $743.47M $12.92 —
STVN Stevanato Group S.p.A. $759.94M $15.25 —
TCMD TACTILE SYSTEMS TECHNOLOGY INC $583.56M $26.05 —
SGHT Sight Sciences, Inc. $583.02M $10.49 —

News headlines (Yahoo Finance, 1h cache)

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-17 21:01 · Yahoo
Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable
2026-11-13 12:55 · Yahoo
Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?
2026-11-12 16:00 · Yahoo
Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 27.7%: Read This Before Placing a Bet
2026-11-12 13:55 · Yahoo
Delcath Systems to Be Featured on "Health Uncensored with Dr. Drew" in Segment Highlighting Advances in Liver-Directed Cancer Treatment
2026-11-11 21:01 · Yahoo
Delcath (DCTH) Q3 2026 Earnings Call Transcript
2026-11-09 18:13 · Yahoo
Delcath Systems, Inc. Q3 2026 Earnings Call Summary
2026-11-09 17:48 · Yahoo
Delcath Systems Reports 70% Revenue Growth in Q3 2026 and Raises Full-Year Guidance to $115 Million–$117 Million
2026-11-09 15:44 · Yahoo
Delcath Systems Q3 Earnings Call Highlights
2026-11-09 15:14 · Yahoo
Delcath Systems, Inc. (DCTH) Q3 Earnings and Revenues Top Estimates
2026-11-09 13:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.